Act like an autocrine or paracrine agent on adjacent viable hepatocytes to exert its protective effects. In the survival analysis, about half of the mice died from repetitive CCl4 injuries within 72 hours while treatments of iPS or 4EGI-1 rIP-10 effectively reduced their mortality. Collectively, our study results implicated that by the help of IP-10, iPS alleviated the intensity of get 79831-76-8 Injury and promoted hepatocytes to leave their growth-arrested state and become mitotically active to repopulate and restore the function of the acute injured liver. However, there are other unrevealed mechanisms responsible for the beneficial effect of iPS. Further studies are needed to clarify the 1676428 exact interactions among iPS, IP-10 and hepatocytes in vivo in the injured liver. In conclusion, our results demonstrated that iPS transfusion reduced serum ALT, AST and the areas of necrosis in acute CCl4injured liver. The treatment of iPS enhances 
the expression of hepatic IP-10, which is an important hepatoprotective mediator to facilitate hepatocyte regeneration, restoration of liver function, and improve survival in the acute CCl4-injured liver.Materials and Methods Experimental Design and Animal StudyMice (C57/B6, 8 to 10 weeks) were housed in cage and were allowed free access to food and water. Mouse was given carbon tetrachloride (CCl4, Sigma) in mineral oil (0.35 ml/g, single dose, i.p.) to induce liver injury. At 4 h post-injury, mice were randomized to receive vehicle (PBS), iPS or iHL (26106 cells/in 100 ml PBS) infusions via tail veins. At given time point, about 100 ml of mice blood were drawn from facial veins for liver biochemistry. When mice were sacrificed, blood were drawn fromIP-10 in Liver Injury Post iPS TransplantationFigure 4. The cellular source and the beneficial effects of IP-10. (A) In vitro cultured iPS secreted IP-10 into culture medium. (B) Mice primary hepatocytes (HC) and none-parenchymal cells (Npc) were isolated from normal and injured mice livers at 24 h post-injury. After iPS infusion, increased expression of IP-10 mRNA were observed mainly in HC from injured liver after iPS treatment (n = 3). (C) Mice none-transformed hepatocytes (AML12) were co-cultured with iPS. iPS increased the viability of the CCl4-injured hepatocytes (n = 3 independent experiment). doi:10.1371/journal.pone.0050577.gIP-10 in Liver Injury Post iPS TransplantationFigure 5. IP-10 is an important factor that mediated the beneficial effects of iPS. (A) Recombinant IP-10 (rIP-10) increased the viability of injured hepatocytes 24 h after CCl4 injury at concentration of 1.0 to 2.5 mM. (B) In injured mice, rIP-10 reduced the degree of liver damage and the effects of rIP-10 were compatible to iPS alone. Combined treatment of rIP-10 and iPS had no additional damage-reducing effects. (C) Anti-IP-10 wasIP-10 in Liver Injury Post iPS Transplantationused to neutralize the effect of IP-10. Application of anti-IP-10 antibody itself did not exert significant effect but significantly attenuated the reduction of ALT level in the CCl4+iPS group at 24 h after CCl4 injury (n = 6, *p,0.05 vs. CCl4 group, #p,0.05 vs. CCl4+iPS group). (D) In CCl4-injured mice received iPS transfusion, the hepatocyte proliferation at the portal region at 48 h after CCl4 injury was significantly reduced by anti-IP-10 antibody. (E) Survival curve of mice treated with CCl4, CCl4+iPS or rIP-10. All the mice were challenged with CCl4 at time 0, 24 and 48 h (n = 32). At 4 h after initial injury, half of the re.Act like an autocrine or paracrine agent on adjacent viable hepatocytes to exert its protective effects. In the survival analysis, about half of the mice died from repetitive CCl4 injuries within 72 hours while treatments of iPS or rIP-10 effectively reduced their mortality. Collectively, our study results implicated that by the help of IP-10, iPS alleviated the intensity of injury and promoted hepatocytes to leave their growth-arrested state and become mitotically active to repopulate and restore the function of the acute injured liver. However, there are other unrevealed mechanisms responsible for the beneficial effect of iPS. Further studies are needed to clarify the 1676428 exact interactions among iPS, IP-10 and hepatocytes in vivo in the injured liver. In conclusion, our results demonstrated that iPS transfusion reduced serum ALT, AST and the areas of necrosis in acute CCl4injured liver. The treatment of iPS enhances the expression of hepatic IP-10, which is an important hepatoprotective mediator to facilitate hepatocyte regeneration, restoration of liver function, and improve 
survival in the acute CCl4-injured liver.Materials and Methods Experimental Design and Animal StudyMice (C57/B6, 8 to 10 weeks) were housed in cage and were allowed free access to food and water. Mouse was given carbon tetrachloride (CCl4, Sigma) in mineral oil (0.35 ml/g, single dose, i.p.) to induce liver injury. At 4 h post-injury, mice were randomized to receive vehicle (PBS), iPS or iHL (26106 cells/in 100 ml PBS) infusions via tail veins. At given time point, about 100 ml of mice blood were drawn from facial veins for liver biochemistry. When mice were sacrificed, blood were drawn fromIP-10 in Liver Injury Post iPS TransplantationFigure 4. The cellular source and the beneficial effects of IP-10. (A) In vitro cultured iPS secreted IP-10 into culture medium. (B) Mice primary hepatocytes (HC) and none-parenchymal cells (Npc) were isolated from normal and injured mice livers at 24 h post-injury. After iPS infusion, increased expression of IP-10 mRNA were observed mainly in HC from injured liver after iPS treatment (n = 3). (C) Mice none-transformed hepatocytes (AML12) were co-cultured with iPS. iPS increased the viability of the CCl4-injured hepatocytes (n = 3 independent experiment). doi:10.1371/journal.pone.0050577.gIP-10 in Liver Injury Post iPS TransplantationFigure 5. IP-10 is an important factor that mediated the beneficial effects of iPS. (A) Recombinant IP-10 (rIP-10) increased the viability of injured hepatocytes 24 h after CCl4 injury at concentration of 1.0 to 2.5 mM. (B) In injured mice, rIP-10 reduced the degree of liver damage and the effects of rIP-10 were compatible to iPS alone. Combined treatment of rIP-10 and iPS had no additional damage-reducing effects. (C) Anti-IP-10 wasIP-10 in Liver Injury Post iPS Transplantationused to neutralize the effect of IP-10. Application of anti-IP-10 antibody itself did not exert significant effect but significantly attenuated the reduction of ALT level in the CCl4+iPS group at 24 h after CCl4 injury (n = 6, *p,0.05 vs. CCl4 group, #p,0.05 vs. CCl4+iPS group). (D) In CCl4-injured mice received iPS transfusion, the hepatocyte proliferation at the portal region at 48 h after CCl4 injury was significantly reduced by anti-IP-10 antibody. (E) Survival curve of mice treated with CCl4, CCl4+iPS or rIP-10. All the mice were challenged with CCl4 at time 0, 24 and 48 h (n = 32). At 4 h after initial injury, half of the re.